Lipoprotein(a) and the atherothrombotic process: Mechanistic insights and clinical implications

Current Atherosclerosis Reports

Volumn 5, Issue 2, 2003, Pages 106-113

  Scanu, Angelo M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A; APOLIPOPROTEIN B100; GLYCAN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; NICOTINIC ACID; PHOSPHOLIPASE A2; PROTEINASE; BIOLOGICAL MARKER;

APHERESIS; ARTERY INTIMA; ARTERY WALL; ATHEROGENESIS; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONCENTRATION (PARAMETERS); CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOREACTIVITY; KRINGLE DOMAIN; LIPID OXIDATION; LIPOLYSIS; MOUSE; NONHUMAN; OBESITY; PATHOGENESIS; PLEIOTROPY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REVIEW; RISK ASSESSMENT; RISK FACTOR; ANIMAL MODEL; BLOOD; CORONARY BLOOD VESSEL; GENETICS; INTIMA; METABOLISM; OXIDATION REDUCTION REACTION;

BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; HUMANS; LIPOPROTEIN(A); MODELS, ANIMAL; OXIDATION-REDUCTION; POLYMORPHISM, GENETIC; TUNICA INTIMA;

EID: 0037645450     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-003-0081-3     Document Type: Review

References (61)

1. Scanu AM, Nakajima K, Edelstein C: Apolipoprotein(a): structure and biology. Frontiers Biosci 2001, 6:546-554.
2. Hobbs HH, White AL: Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 1999, 10:225-236.
3. Marcovina SM, Albers JJ, Wijsman E, et al.: Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996, 37:2569-2585.
4. Hoogeveen RC, Gambhir JK, Gambhir DS, et al.: Evaluation of Lp(a) and other independent risk factors for CHD in Asian Indians and their USA counterparts. J Lipid Res 2001, 42:631-638.
5. Hopkins PN, Wu LL, Hunt SC, et al.: Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1997, 17:2783-2792.
6. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis. A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285:2481-2485.
7. Von Eckardstein A, Assmann G: Clinical implications of elevated lipoprotein (a). Curr Atheroscler Rep 2001, 3:267-270.
8. Baggio G, Donazzan S, Monti D, et al.: Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J 1998, 12:433-437.
9. Thillet J, Doucet C, Chapman J, et al.: Elevated lipoprotein(a) levels and small apo(a) isoforms are compatible with longevity evidence from a large population of French centenarians. Artherosclerosis 1997, 136:389-394.
10. Kraft HG, Sandholzer C, Menzel HJ, et al.: Apolipoprotein(a) alleles determine lipoprotein(a) particle density and concentration in plasma. Arterioscler Thromb 1992, 12:302-306.
11. Kronenberg F, Kronenberg MF, Kiechl S, et al.: Role of lipoprotein (a) and apolipoprotein (a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999, 100:1154-1160.
12. Gazzaruso C, Geroldi D, Garzaniti A, et al.: Apolipoprotein (a) phenotypes as genetic markers of coronary atherosclerosis severity. Int J Cardiol 1998, 64:277-284.
13. Wild SH, Fortmann SP, Marcovina SM: A prospective case-control study of lipoprotein (a) levels and apo (a) size and risk of coronary heart disease in Stanford five-city project participants. Arterioscler Thromb Vasc Biol 1997, 17:239-245.
14. Paultre F, Tuck CH, Boden-Albala B, et al.: Relation of apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arterioscler Thromb Vasc Biol 2002, 22:141-146.
15. Rubin J, Paultre F, Tuck CH, et al.: Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res 2002, 43:234-244.
16. Martin S, Pedro-Botet J, Joven J, et al.: Heterozygous apolipoprotein (a) status and protein expression as a risk factor for premature coronary heart disease. J Lab Clin Med 2002, 139:181-187.
17. Scanu AM, Pfaffinger D, Lee JC, et al.: A single point mutation (trp72->arg) in human apo(a) kringle 4-37 associated with a lysine binding defect in Lp(a). Biochim Biophys Acta 1994, 1227:41-45.
18. Xia J, May LF, Koschinsky ML: Characterization of the basis of lipoprotein (a) lysine-binding heterogenity. J Lipid Res 2000, 41:1578-1584.
19. Armstrong VW, Harrach B, Robeneck H, et al.: Heterogeneity of human lipoprotein Lp(a): cytochemical and biochemical studies on the interaction of two Lp(a) species with the LDL receptor. J Lipid Res 1990, 31:429-441.
20. Boonmark NW, Lou JX, Yang ZJ, et al.: Modification of apolipoprotein(a) lysine-binding site reduces atherosclerosis in transgenic mice. J Clin Invest 1997, 100:558-564.
21. Nakajima K, Hinman J, Pfaffinger D, et al.: Changes in plasma triglyceride levels shift lipoprotein(a) density in parallel with that of low-density lipoprotein independently of apolipoprotein(a) size. Arterioscler Thromb Vasc Biol 2001, 21:1238-1243.
22. Edelstein C, Nakajima K, Pfaffinger D, et al.: Oxidative events cause degradation of apolipoprotein B100 but not apolipoprotein(a) and facilitate enzymatic cleavage of both proteins. Arterioscler Thromb Vasc Biol 2001, 21:641.
23. Fless GM, Kirk EW, Klezovitch O, et al.: Effect of phospholipase A2 digestion on the conformation and lysine/fibrinogen binding properties of human lipoprotein(a). J Lipid Res 1999, 40:583-592.
24. Aggerbeck LP, Kezdy FJ, Scanu AM: Enzymatic probes of lipoprotein structure: Hydrolysis of human serum lowdensity lipoprotein-2 by phospholipase A2. J Biol Chem 1976, 251:3823-3830.
25. Hakala JK, Öörni K, Pentikäinen MO, et al.: Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 2001, 21:1053-1058.
26. Hanasaki K, Yamada K, Yamamoto S, et al.: Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J Biol Chem 2002, 277:29116-29124.
27. Edelstein C, Italia JI, Scanu AM: Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase: generation of mini Lp(a) particles and apo(a) fragments. J Biol Chem 1997, 272:11079-11087.
28. Edelstein C, Shapiro SD, Klezovitch O, et al.: Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology. J Biol Chem 1999, 274:10019-10023.
29. Edelstein C, Italia JA, Klezovitch O, et al.: Functional and metabolic differences between elastase-generated fragments of human lipoprotein(a) and apolipoprotein(a). J Lipid Res 1996, 37:1786-1801.
30. Garner B, Merry AH, Royle L, et al.: Structural elucidation of the N- and O-glycans of human apolipoprotein(a). Role of O-glycans in conferring protease resistance. J Biol Chem 2001, 276:22200-22208.
31. Haberland ME, Fless GM, Scanu AM, et al.: Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem 1992, 267:4143-4151.
32. Hoover-Plow J, Khaitan A, Fless GM: Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost 1998, 79:640-648.
33. Scanu AM, Edelstein C: Learning about the structure and biology of human lipoprotein(a) through dissection by enzymes of the elastase family: facts and speculations. J Lipid Res 1997, 38:2193-2206.
34. Scanu AM, Edelstein C, Klezovitch O: Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix. Trends Cardiovasc Med 1999, 9:196-200.
35. Williams KJ, Tabas I: The response-to retention- hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995, 15:551-561.
36. Kang C, Dominguez M, Loyau S, et al.: Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner. Arteroscler Thromb Vasc Biol 2002, 22:1232-1238.
37. Miles LA, Plow EF: Lp(a): an interloper into the fibrinolytic system? Thromb Haemost 1990, 63:331-335.
38. Rand ML, Sangrar W, Hancock MA, et al.: Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 1998, 18:1393-1399.
39. Buechler C, Ullrih H, Ritter M, et al.: Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 2001, 97:981-986.
40. Caplice NM, Panetta C, Peterson TE, et al.: Lipoprotein(a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis. Blood 2001, 98:2980-2987.
41. Haque NS, Zhang X, French DL, et al.: CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation 2000, 102:786-792.
42. Klezovitch O, Edelstein C, Scanu AM: Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a): evidence for a critical involvement of elements of its C-terminal domain. J Biol Chem 2001, 276:46864-46869.
43. Lawn RM, Wade DP, Hammer RE, et al.: Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992, 360:670-672.
44. Berg K, Svindland A, Smith AJ, et al.: Spontaneous atherosclerosis in the proximal aorta of LPA transgenic mice on a normal diet. Atherosclerosis 2002, 163:99-104.
45. Mancini FP, Newland DL, Mouser V, et al.: Relative contributions of apolipoprotein(a) and apolipoprotein B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 1995, 15:1911-1916.
46. Sanan DA, Newland DL,Tao R, et al.: Low density lipoprotein receptor-negative mice expressing human apolipoprotein B100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci USA 1998, 95:4544-4549.
47. Kusumi Y, Scanu AM, McGill HC, et al.: Atherosclerosis in a rhesus monkey with genetic hypercholesterolemia and elevated plasma-Lp(a). Atherosclerosis 1993, 99:165-174.
48. Fan J, Shimoyamada H, Sun H, et al.: Transgenic rabbits expressing human apolipoprotein (a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 2001, 21:88-94.
49. Fan J, Sun H, Unoki H, et al.: Enhanced atherosclerosis in LP(a) WHHL transgenic rabbits. Ann NY Acad Sci 2001, 947:362-365.
50. Fu L, Jamieson DG, Usher DC, et al.: Gene expression of apolipoprotein (a) within the wall of human aorta and carotid arteries. Atherosclerosis 2001, 158:303-311.
51. Rader DJ, Dugi KA: The endothelium and lipoproteins: insights from recent cell biology and animal studies. Sem Thromb Hemost 2000, 26:521.
52. Argraves MK, Kozarsky KF, Fallon JT, et al.: The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest 1997, 100:2170-2181.
53. Jamieson DG, Usher DC, Rader DJ, et al.: Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 1995, 147:1567-1574.
54. Haque NS, Fallon JT, Taubman MB, et al.: The chemokine receptor CCR8 mediates human endothelial cell chemotaxix induced by I-309 and Kaposi sarcoma herpes virus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium. Blood 2001, 97:39-45.
55. Scanu AM: Atherothrombogenicity of lipoprotein (a): the debate. Am J Cardiol 1998, 82:26-33.
56. Fortunato JE, Bassiouny HS, Song RH, et al.: Apolipoprotein(a) fragments in relation to human carotid plaque instability. J Vasc Surg 2000, 32:555-563.
57. Marcovina SM, Albers JJ, Scanu AM, et al.: Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000, 46:1956-1967.
58. Scanu AM, Hinman J: Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels. Lipids 2002, 37:439-444.
59. Scanu AM: The role of lipoprotein (a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr Cardiol Reports 2001, 3:385-390.
60. Morishita R, Yamada S, Yamamoto K, et al.: Novel therapeutic strategies for atherosclerosis. Ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. Circulation 1998, 98:1898-1904.
61. Frank S, Gauster M, Strauss J, et al.: Adenovirus-mediated apo(a)-antisense-RNA expression efficiently inhibits apo(a) synthesis in vitro and in vivo. Gene Therapy 2001, 8:425-430.